Table 3 Peak creatine kinase and pre-discharge and follow-up CMR data

Variable

Immediate CR

(n = 63)

Staged CR

(n = 30)

p

Peak CK (IU/L)

939 (627–1567)

1508 (938–2280)

0.05

Pre-discharge CMR

Total Infarct Size (% LVM)

11.6 (6.8–18.2)

13.5 ± 11.4

19.7 (11.7–37.6)

22.6 ± 14.5

0.016

(0.012)*

Time from PPCI (days)

2.3 (1.7–3.2)

4.1 (2.7–5.4)

<0.001

Infarct on LGE (%)

60 (95.2)

30 (100)

0.22

Patients with >1 acute infarct

7 (11.1)

9 (30.0)

0.024

IRA Infarct size (% LVM)

11.1 (5.4–17.4)

12.5 ± 10.0

19.1 (8.8–35.2)

20.9 ± 14.6

0.039

(0.05)*

Non-IRA Infarct size (% LVM)

0.9 ± 3.2

1.7 ± 3.6

0.11

(0.65)*

Total acute infarcts (% LVM)

11.6 (6.8–17.6)

13.0 ± 10.3

19.1 (10.2–37.1)

21.7 ± 14.8

0.006

(0.025)*

Area at risk (% LVM)

31.4 ± 12.5

33.1 ± 10.8

0.57

MSI^§ (%)

61.7 (37.4–75.5)

35.1 (5.9–66.4)

0.008

(0.034)*

MVO present (n %)

34/63 (54.0)

21/30 (70.0)

0.14

MVO (% LVM)

0.07 (0.00–0.93)

0.44 (0.00–6.1)

0.032

(0.024)*

LVMI (g/m2)

52.5 (47.7–61.0)

51.5 (45.6–63.0)

0.55

LVEDVI (ml/m2)

89.9 (78.4–110.0)

89.7 (82.8–102.9)

0.43

LVEF (%)

47.4 ± 9.4

42.2 ± 10.2

0.019

Follow-up CMR

n = 53

n = 26

LVMI (g/m2)

45.2 (38.8–52.3)

47.4 (40.9–51.6)

0.71

LVEDVI (ml/m2)

92.5 (80.5–105.5)

93.9 (83.3–113.6)

0.28

LVEF (%)

50.9 ± 9.4

46.7 ± 8.9

0.06

Infarct on LGE (n,%)

51 (96.2)

26 (100)

0.32

Patients with >1 infarct (%)

9 (17.0)

9 (34.6)

0.08

IS (% LVM)

5.7 (2.4–10.4)

13.5 (4.6–23.3)

0.004

(0.044)*